1. Phxa34
2. Phxa41
3. Xalatan
1. 130209-82-4
2. Xalatan
3. Phxa41
4. Phxa-41
5. Xa41
6. Phxa 41
7. Xa-41
8. Latanoprost (isopropyl Ester)
9. Isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
10. Propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
11. Latanoprost, (+/-)-
12. 6z5b6hvf6o
13. 8s5fb3xxg8
14. Latanoprost, Ethanol Solution
15. Chebi:6384
16. Propan-2-yl (5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
17. T-2345
18. T2345
19. 5-heptenoic Acid, 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl Ester, (5z)-
20. Isopropyl (5z,9alpha,11alpha,15r)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
21. Catioprost
22. (z)-isopropyl 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
23. 155551-81-8
24. 5-heptenoic Acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl Ester
25. Smr000466354
26. Xalatan (tn)
27. Unii-6z5b6hvf6o
28. Latanoprostum
29. Nova-21027
30. Latanoprost [usan:inn:ban]
31. Xa 41
32. Phxa34 [as 15(r,s)-isomer]
33. Propan-2-yl (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
34. Ar-202
35. Mfcd00216074
36. Xelpros
37. L-ppds
38. Latanoprost [mi]
39. Latanoprost [inn]
40. Latanoprost [jan]
41. Latanoprost [usan]
42. Unii-8s5fb3xxg8
43. Latanoprost [vandf]
44. Chembl1051
45. Latanoprost [mart.]
46. Schembl24698
47. Latanoprost [usp-rs]
48. Latanoprost [who-dd]
49. Mls000759468
50. Mls001424106
51. Latanoprost (jan/usp/inn)
52. Gtpl1961
53. Dtxsid1041057
54. Latanoprost [orange Book]
55. Hms2051h11
56. Hms2089j17
57. Hms3715n22
58. Latanoprost [ep Monograph]
59. Latanoprost [usp Monograph]
60. Amy30089
61. Ex-a1770
62. Hy-b0577
63. Xalacom Component Latanoprost
64. Bdbm50240648
65. S4709
66. Zinc12468792
67. Latanoprost, >=98% (hplc), Oil
68. Rocklatan Component Latanoprost
69. Akos024458331
70. Ccg-100946
71. Db00654
72. Nc00196
73. Latanoprost Component Of Rocklatan
74. Ncgc00246969-01
75. Ncgc00246969-06
76. (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptanoic Acid 1-methylethyl Ester
77. As-75099
78. L0262
79. D00356
80. Ab00640005-04
81. Ab00640005-06
82. 209l824
83. A806039
84. Q634959
85. Sr-01000759428
86. J-005764
87. Sr-01000759428-4
88. Latanoprost, United States Pharmacopeia (usp) Reference Standard
89. Tris(2,4-dimethylphenyl)phosphine-5,5',5""""-trisulfonic Acid Trisodium Salt
90. (1r,2r,3r,5s,3''r)-7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic Acid Isopropyl Ester
91. (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic Acid Propan-2-yl Ester
92. 5-heptenoic Acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl Ester, (1r-(1-alpha(z),2-beta(r*),3-alpha,5-alpha))-
93. 5-heptenoic Acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-1-methylethyl Ester, (1r-(1.alpha.(z),2.beta.(r*),3.alpha.,5.alpha.))-
94. Isopropyl (5z,9alpha,11alpha,15r)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate;xalatan
95. Propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-bis(oxidanyl)-2-[(3r)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoate
| Molecular Weight | 432.6 g/mol |
|---|---|
| Molecular Formula | C26H40O5 |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 14 |
| Exact Mass | 432.28757437 g/mol |
| Monoisotopic Mass | 432.28757437 g/mol |
| Topological Polar Surface Area | 87 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 526 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Latanoprost |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; ophthalmic |
| Strength | 0.005% |
| Market Status | Tentative Approval; Prescription |
| Company | Alcon Res; Par Pharm; Bausch And Lomb; Luitpold; Dr Reddys Labs; Mylan; Akorn |
| 2 of 4 | |
|---|---|
| Drug Name | Xalatan |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.005% |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 3 of 4 | |
|---|---|
| Drug Name | Latanoprost |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; ophthalmic |
| Strength | 0.005% |
| Market Status | Tentative Approval; Prescription |
| Company | Alcon Res; Par Pharm; Bausch And Lomb; Luitpold; Dr Reddys Labs; Mylan; Akorn |
| 4 of 4 | |
|---|---|
| Drug Name | Xalatan |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.005% |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. Latanoprost may be combined in a product with [Netarsudil], a rho kinase inhibitor, for the same indications. In addition to the above indications, the Canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty.
FDA Label
Treatment of glaucoma
Latanoprost effectively decreases intraocular pressure by increasing uveoscleral outflow. A decrease in intraocular pressure has been measured within 34 hours post-administration, reaches a maximum decrease at 812 hours, and can be maintained for a period of 24 hours. **A note on eye and periorbital changes** Between 3 to 10% of patients taking latanoprost have experienced iris pigmentation after about 3-4 months of latanoprost use. Patients should be notified of this risk before initiating treatment. It may occur in both patients with light-colored irides (green-brown or blue/grey-brown) or dark-colored (brown) irides, but is less pronounced in the latter group. This drug may also cause other ocular effects including infrequent conjunctival hyperemia, pigmentation of periocular tissues, eyelash changes, hypertrichosis, and ocular irritation.
Ophthalmic Solutions
Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (See all compounds classified as Ophthalmic Solutions.)
S01EE01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01E - Antiglaucoma preparations and miotics
S01EE - Prostaglandin analogues
S01EE01 - Latanoprost
Absorption
This drug is rapidly absorbed in the cornea as an isopropyl ester prodrug and is then activated by the process of hydrolysis. A small amount of this drug is systemically absorbed. The Cmax of latanoprost in the systemic circulation is reached after 5 minutes and is measured to be 53 pg/mL. The Cmax in the aqueous humor is attained within 2 hours after administration. and has been estimated to be 15-30 ng/mL.
Route of Elimination
After hepatic beta-oxidation, the metabolites of latanoprost are primarily found to be excreted by the kidneys. About 88% of the latanoprost dose is recovered in the urine after topical administration. About 15% of a dose is reported to be excreted in the feces.
Volume of Distribution
The volume of distribution of latanoprost is 0.16 0.02 L/kg. The activated acid form of latanoprost can be measured in aqueous humor in the initial 4 hours post-administration, and it is measured in the plasma only for 1 hour following ophthalmic administration. This drug is more lipophilic than its parent prostaglandin and easily penetrates the cornea. It has been shown to cross the placenta in rats.
Clearance
The systemic clearance of latanoprost is 7 mL/min/kg.
After corneal uptake, this prodrug is hydrolyzed and activated by esterases to become a pharmacologically active drug. The small portion of this drug that is able to reach the circulation is found to be metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites through fatty acid beta-oxidation.
The elimination half-life of latanoprost from the plasma is about 17 minutes. The elimination half-life of latanoprost from the eye is estimated at 23 hours.
Elevated intraocular pressure leads to an increased risk of glaucomatous visual field loss. The higher the intraocular pressure, the higher the risk of damage to the optic nerve and loss of visual field. Latanoprost selectively stimulates the prostaglandin F2 alpha receptor and this results in a decreased intraocular pressure (IOP) via the increased outflow of aqueous humor, which is often implicated in cases of elevated intraocular pressure. Possible specific mechanisms of the abovementioned increased aqueous outflow are the remodeling of the extracellular matrix and regulation of matrix metalloproteinases. These actions result in higher tissue permeability related to humor outflow pathways, which likely change outflow resistance and/or outflow rates.
LOOKING FOR A SUPPLIER?
